Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026

Core Viewpoint - It has been one year since the last coverage of Bristol-Myers Squibb (BMY), with the stock rated as a Hold following Q4 2024 earnings, which caused concern among investors due to declining projections for 2025 [1] Group 1 - The article highlights the author's background, including a Ph.D. in organic synthesis from Stanford University and experience in major pharmaceutical companies and biotech startups [1] - The author is a co-founder of 1200 Pharma, which successfully garnered significant investment [1] - The author remains focused on market trends, particularly in biotechnology stocks [1]